Lutikizumab (ABT-981): A Comprehensive Profile of a Dual IL-1α/β Antagonist from Osteoarthritis to Hidradenitis Suppurativa

Executive Summary

Lutikizumab is an investigational, next-generation biologic agent developed by Abbott Laboratories and its successor, AbbVie, representing a significant advancement in therapeutic antibody engineering.[1] Structurally, it is a humanized, tetravalent bispecific antibody, engineered using a proprietary dual-variable domain immunoglobulin (DVD-Ig) platform.[2] This sophisticated design enables Lutikizumab to function as a potent and specific inhibitor of two distinct but related pro-inflammatory cytokines: Interleukin-1 alpha (

IL−1α) and Interleukin-1 beta (IL−1β).[5] By simultaneously neutralizing both mediators, Lutikizumab is designed to provide a more comprehensive blockade of the IL-1 signaling pathway than agents targeting a single cytokine.

The clinical development of Lutikizumab has been characterized by a critical and strategic pivot. The drug was initially investigated for the treatment of osteoarthritis (OA), a therapeutic area where the IL-1 pathway was hypothesized to play a key role. However, despite Phase 2 clinical trials demonstrating successful target engagement and biological activity, Lutikizumab failed to produce clinically meaningful improvements in pain or structural outcomes in patients with either knee or hand OA, leading to the discontinuation of the program for this indication.[1]

In a strategic shift, AbbVie redirected the development program toward immune-mediated diseases with a more clearly defined and dominant IL-1 pathogenic signature. This move has proven highly successful in the context of hidradenitis suppurativa (HS), a severe and debilitating inflammatory skin disease. A Phase 2 study in patients with moderate-to-severe HS, notably a population that had previously failed anti-TNF therapy, yielded statistically significant and clinically meaningful positive results.[6] This success has established HS as the lead indication for Lutikizumab and has prompted its advancement into a large-scale global Phase 3 program.[1]

Currently, Lutikizumab remains an unapproved, investigational agent. Alongside the pivotal Phase 3 HS program, AbbVie is leveraging an efficient platform study design to explore its efficacy and safety across a broad spectrum of other immune-mediated diseases. Active Phase 2 trials are underway in rheumatoid arthritis (RA), psoriatic arthritis (PsA), ulcerative colitis (UC), and atopic dermatitis (AD), positioning Lutikizumab as a molecule whose clinical success is fundamentally tied to the precise targeting of diseases where the IL−1α/β axis is a dominant driver of pathology.[1]

Molecular Engineering and Pharmacological Profile

The therapeutic potential of Lutikizumab is rooted in its novel molecular architecture and highly specific mechanism of action. As a product of advanced antibody engineering, its structure and function are designed to overcome limitations of previous therapies by offering a more complete blockade of a central inflammatory pathway.

Identification and Nomenclature

Lutikizumab is identified by a consistent set of names and codes across scientific literature, clinical trial registries, and chemical databases, ensuring precise tracking and reference.

• Primary Names: The designated International Nonproprietary Name (INN) is Lutikizumab.[13]
• Developmental Codes: During its research and development phases, the compound has been primarily referred to by the codes ABT-981 and A-1234138.[1]
• Chemical and Regulatory Identifiers:
• CAS Number: 1791411-57-8.[13]
• DrugBank ID: DB16224.[13]
• UNII (Unique Ingredient Identifier): 15FAZ725S0.[13]

Structural Characterization: A Novel DVD-IgG1k Bispecific Antibody

Lutikizumab is classified as a biotech drug and is a humanized monoclonal antibody of the immunoglobulin G1 kappa (IgG1k) isotype.[13] Its defining feature is its construction on AbbVie's proprietary dual-variable domain immunoglobulin (DVD-Ig) platform, which distinguishes it from conventional monoclonal antibodies and other bispecific formats.[2]

The DVD-Ig technology involves engineering the N-terminus of each light and heavy chain of a standard monoclonal antibody to include an additional, distinct variable domain. The result is a single molecule where each of the two arms of the antibody contains two tandem variable domains. This creates a symmetric, tetravalent structure with four antigen-binding sites in total. Because the two variable domains on each arm are engineered to recognize different targets, the molecule is bispecific, capable of simultaneously binding two distinct antigens—in this case, IL−1α and IL−1β.[4] This sophisticated architecture was designed to test the hypothesis that dual, comprehensive inhibition of the IL-1 pathway would yield superior clinical outcomes in diseases where both cytokines contribute to pathology, a premise that could not be adequately tested with monospecific agents.

The molecular composition of Lutikizumab has been precisely characterized:

• Chemical Formula: C6454​H9900​N1694​O2017​S42​.[14]
• Molecular Weight: The Kyoto Encyclopedia of Genes and Genomes (KEGG) database reports a molecular weight of 144,840.60 Da and an exact mass of 144,751.2450 Da.[14] Another source reports a molecular weight of 196.8 kDa, a discrepancy that may relate to different methods of calculation or reporting, though the KEGG value is likely more precise for the unmodified protein dimer.[17]
• Amino Acid Sequence: The complete primary structure of the protein has been determined, including the sequences of its constituent chains and the arrangement of its disulfide bonds.[14]
• Heavy Chain Sequence: EVQLQESGPG LVKPSETLSL TCAVTGYSIT SGYSWHWIRQ FPGNGLEWMG YIHSSGSTNY NPSLKSRISI SRDTSKNQFF LKLSSVTAAD TAVYYCAGYD DYFEYWGQGT TVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PEAAGGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK.
• Light Chain Sequence: DIQMTQSPSS LSASVGDRVT ITCKASQNVG FNVAWYQQKP GKSPKALIYS ASYRYSGVPS RFSGSGSGTD FTLTISSLQP EDFAEYFCQQ YNWYPFTFGQ GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC.
• Disulfide Bridges: The complex structure is stabilized by numerous inter- and intra-chain disulfide bonds: H22-H96, H143-H199, H219-L214, H225-H'225, H228-H'228, H260-H320, H366-H424, H'22-H'96, H'143-H'199, H'219-L'214, H'260-H'320, H'366-H'424, L23-L88, L134-L194, L'23-L'88, L'134-L'194.

Mechanism of Action: Dual Neutralization of IL-1α and IL-1β

The therapeutic activity of Lutikizumab derives from its specific and simultaneous targeting of the two key ligands of the IL-1 signaling pathway.

• The IL-1 Pathway in Inflammation: The Interleukin-1 family of cytokines, particularly IL−1α and IL−1β, are potent pro-inflammatory mediators and established drivers of pain.[7] Although they are distinct gene products, both cytokines exert their biological effects by binding to the same cell surface receptor, the IL-1 type 1 receptor (IL-1R1).[3] This binding event initiates a downstream signaling cascade that results in the transcription and release of numerous secondary inflammatory molecules, including other cytokines, chemokines, and matrix-degrading proteases. This cascade amplifies the inflammatory response, contributing directly to tissue damage, cartilage destruction, bone resorption, and the clinical symptoms of pain and swelling characteristic of many immune-mediated diseases.[3]
• Lutikizumab's Specific Action: Lutikizumab is engineered to bind and potently neutralize both circulating IL−1α and IL−1β.[3] By sequestering these ligands, it prevents them from engaging with IL-1R1, thereby effectively shutting down the downstream inflammatory cascade.[5] This dual blockade is hypothesized to provide a more robust anti-inflammatory effect than targeting either cytokine alone.
• Specificity and Binding Affinity: A critical feature of Lutikizumab is its high degree of specificity. It binds to IL−1α and IL−1β without interfering with the activity of other IL-1 family members, most importantly the endogenous IL-1 receptor antagonist (IL-1Ra), which serves as a natural brake on the IL-1 system.[3] In vitro studies have quantified its high-affinity binding, demonstrating an effective concentration for 50% binding ( EC50​) of 1.97 ng/mL for immobilized human IL−1α and 3.63 ng/mL for immobilized human IL−1β.[18]

Pharmacodynamics and In-Vivo Target Engagement

Clinical studies have consistently confirmed that subcutaneous administration of Lutikizumab results in robust and dose-dependent biological activity, providing clear evidence of in-vivo target engagement.

• Biomarker Evidence: Across Phase 2 trials, Lutikizumab treatment led to significant reductions in serum levels of high-sensitivity C-reactive protein (hsCRP), a well-established systemic biomarker of inflammation.[3] This demonstrates that the blockade of IL-1 signaling has a measurable impact on downstream inflammatory processes.
• Hematological Effects: A consistent and expected pharmacodynamic effect is the reduction of blood neutrophil counts, a phenomenon known as neutropenia.[3] This occurs because IL-1 signaling is involved in the mobilization and regulation of neutrophils. In clinical trials, this effect appeared to plateau at the 100 mg dose, with no further reductions observed at 200 mg, suggesting target saturation.[26]
• Target Level Reduction: Direct evidence of target engagement was provided by measurements showing that Lutikizumab administration significantly decreased the levels of free IL−1α and IL−1β in the serum, confirming that the drug effectively binds and clears its intended targets from circulation.[3]

Clinical Development History: The Osteoarthritis Program

The initial therapeutic target for Lutikizumab was osteoarthritis (OA), a prevalent and debilitating degenerative joint disease. The development program in this indication provided crucial insights into the drug's activity and the complexities of OA pathophysiology, ultimately leading to a strategic redirection.

Rationale for Targeting IL-1 in Osteoarthritis

The scientific rationale for investigating an IL-1 inhibitor in OA was compelling. Preclinical studies and analyses of human OA tissue had implicated both IL−1α and IL−1β as key mediators of the inflammatory and destructive processes in the joint.[3] These cytokines were shown to promote synovitis (inflammation of the joint lining), stimulate the production of cartilage-degrading enzymes, and contribute to bone resorption.[3] Furthermore, elevated concentrations of IL-1 were found in the serum and synovial fluid of patients with OA, suggesting the pathway was pathologically active.[7] Early-phase clinical studies of Lutikizumab supported moving forward; a Phase 1 multiple ascending-dose study in patients with knee OA found the drug to be generally well tolerated and associated with the expected pharmacodynamic effects, including reductions in hsCRP, neutrophils, and markers of synovitis, providing proof of biological activity.[3]

Phase 2 Trial in Knee Osteoarthritis (NCT02087904)

The largest study in the OA program was a Phase 2 trial designed to assess the efficacy and safety of Lutikizumab in 350 patients with moderate-to-severe (Kellgren-Lawrence grade 2-3) knee OA and evidence of synovitis.[4] In this randomized, placebo-controlled study, patients received subcutaneous injections of Lutikizumab at doses of 25 mg, 100 mg, or 200 mg, or a matching placebo, every two weeks for 50 weeks.

The trial ultimately failed to demonstrate a clear and sustained clinical benefit.

• Efficacy Outcomes: The study's co-primary endpoints were the change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score at week 16 and the change in MRI-assessed synovitis at week 26.[26] While the 100 mg dose of Lutikizumab showed a modest, statistically significant improvement in the WOMAC pain score compared to placebo at the 16-week timepoint ( P=0.050), this effect was not observed with the 25 mg or 200 mg doses.[26] Critically, this limited analgesic effect was not sustained beyond week 16. Furthermore, there were no significant differences between any Lutikizumab group and placebo in changes to MRI-assessed synovitis or other key symptom- and structure-related endpoints at weeks 26 and 52.[26]
• Safety Outcomes: The safety profile was notable for a higher frequency of injection site reactions and neutropenia in the Lutikizumab arms compared to placebo. Discontinuations due to these adverse events were also more common with the active drug.[9]

Phase 2a Trial in Erosive Hand Osteoarthritis (NCT02384538)

To explore the drug's potential in a more inflammatory subset of OA, a Phase 2a study was conducted in 132 patients with erosive hand osteoarthritis (HOA).[3] Patients were randomized to receive either Lutikizumab 200 mg or placebo subcutaneously every two weeks for 24 weeks.

The results of this trial mirrored the findings from the knee OA study.

• Efficacy Outcomes: The study did not meet its primary endpoint, which was the change in the Australian/Canadian Osteoarthritis Hand Index (AUSCAN) pain score at week 16. There was no statistically significant difference between the Lutikizumab and placebo groups.[3] Similarly, no significant benefits were observed for other clinical or imaging endpoints.[3]
• Pharmacodynamic Confirmation: Despite the lack of clinical efficacy, the study provided robust confirmation of the drug's biological activity. Lutikizumab treatment led to significant decreases in serum hsCRP, free IL−1α, and free IL−1β levels, as well as a reduction in blood neutrophils, confirming that adequate blockade of the IL-1 pathway had been achieved.[3]

Analysis of Discontinuation

Following these disappointing Phase 2 results, AbbVie officially discontinued the development of Lutikizumab for osteoarthritis.[1] The collective findings from the OA program demonstrate a critical disconnect between target engagement and clinical efficacy. The pharmacodynamic data from both the knee and hand OA trials unequivocally show that Lutikizumab successfully reached its targets and produced the expected downstream biological effects. This proves that the drug "works" on a molecular and physiological level. However, this potent biological activity failed to translate into meaningful clinical benefits for patients in terms of pain relief, functional improvement, or modification of joint damage.

This outcome strongly suggests that the failure was not due to a flaw in the drug itself, but rather a flaw in the underlying drug-disease hypothesis. The data from these high-quality clinical trials challenge the premise that the IL−1α/β pathway is a primary, rate-limiting driver of the clinical symptoms and structural progression in the majority of patients with osteoarthritis. While the IL-1 pathway is undoubtedly involved in OA pathophysiology, its inhibition alone appears insufficient to alter the course of the disease. This crucial lesson likely informed AbbVie's strategic decision to pivot the program toward inflammatory conditions with a stronger and more clearly defined IL-1 pathogenic signature. A subsequent Bayesian network meta-analysis published in 2020 reinforced this conclusion, finding that Lutikizumab offered no improvement in pain or function over placebo for OA.[7]

Pivotal Indication: Hidradenitis Suppurativa (HS)

Following the discontinuation of the osteoarthritis program, Lutikizumab's development was strategically refocused on hidradenitis suppurativa (HS), a chronic, recurrent, and profoundly debilitating inflammatory skin disease. This pivot was based on a strong scientific rationale and has been validated by highly encouraging clinical trial results.

Pathophysiological Rationale in HS

Hidradenitis suppurativa, sometimes called acne inversa, is characterized by the formation of painful, deep-seated inflammatory nodules, abscesses, and draining tunnels, typically in intertriginous skin areas.[11] Unlike in osteoarthritis, where the role of IL-1 is part of a complex, multifactorial pathology, studies have demonstrated that both

IL−1α and IL−1β are significantly elevated in active HS lesions.[6] This suggests that the IL-1 pathway is a more central and dominant driver of the intense inflammation that characterizes the disease.

Furthermore, there remains a significant unmet medical need in the management of HS. Many patients do not respond adequately or lose response to existing therapies, including the current standard-of-care biologics that target Tumor Necrosis Factor (TNF).[10] This creates a clear clinical and commercial opportunity for a therapy with a novel mechanism of action, particularly one that could be effective in this treatment-refractory population.

Phase 2 Trial (NCT05139602) In-Depth Analysis

The potential of Lutikizumab in HS was evaluated in a robust Phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study.[6] The trial enrolled 153 adult patients with moderate-to-severe HS who had specifically failed prior treatment with anti-TNF therapy, representing a particularly difficult-to-treat population. A substantial majority of these patients (70.6%) presented with severe, Hurley Stage 3 disease, the most extensive form of HS.[12]

Participants were randomized to one of four subcutaneous treatment arms for a 16-week period: Lutikizumab 100 mg every other week (EOW), 300 mg EOW, 300 mg every week (EW), or placebo.[6] The study's results demonstrated a clear, dose-dependent efficacy signal for the 300 mg doses.

The success of Lutikizumab in this trial was particularly noteworthy because it was achieved in a patient population with a high unmet need. By specifically enrolling and demonstrating efficacy in patients who had already failed anti-TNF therapy, the trial not only validated the IL-1 pathway as a target but also carved out a clear potential position for Lutikizumab within the HS treatment algorithm: as a second-line biologic for patients who are refractory to the current standard of care. This suggests that its mechanism of action is distinct from and can overcome resistance to TNF inhibition, a finding that significantly de-risks its future clinical and commercial pathway.

The key efficacy findings at week 16 are summarized below.

Endpoint (at Week 16)	Placebo (N=40)	Luti 100 mg EOW (N=37)	Luti 300 mg EOW (N=37)	Luti 300 mg EW (N=39)
HiSCR 50 (%) (Primary)	35.0	27.0	59.5	48.7
Treatment Difference vs. Placebo (p-value)	-	-9.7 (p=0.345)	24.1 (p=0.027)	13.8 (p=0.197)
Skin Pain NRS30 (%) (Secondary)	12.9	22.2	34.5	34.8
Treatment Difference vs. Placebo (p-value)	-	9.4 (p=0.330)	21.8 (p=0.039)	19.8 (p=0.066)
HiSCR 75 (%) (Additional)	17.5	16.2	45.9	38.5
Treatment Difference vs. Placebo (p-value)	-	-2.2 (p=0.795)	28.2 (p=0.005)	21.0 (p=0.031)
Data sourced from AbbVie press release and related materials.6 HiSCR 50/75 (Hidradenitis Suppurativa Clinical Response) represents at least a 50%/75% reduction in total abscess and inflammatory nodule count with no increase in abscesses or draining fistulas. NRS30 represents at least a 30% reduction in skin pain among patients with a baseline score of ≥3.

As shown in the table, the 300 mg EOW dose met the primary endpoint with statistical significance, achieving a HiSCR 50 response rate of 59.5% compared to 35.0% for placebo. This dose also demonstrated statistically significant improvements in the secondary endpoint of skin pain reduction (NRS30) and the higher efficacy bar of HiSCR 75. The 300 mg EW dose also showed numerically higher response rates across all key endpoints. In contrast, the 100 mg EOW dose did not show efficacy greater than placebo.[6]

Consolidated Safety Profile in HS

In the Phase 2 HS study, all doses of Lutikizumab were generally well-tolerated.[10] The overall rate of treatment-emergent adverse events (TEAEs) was comparable between the combined Lutikizumab treatment arms (70.8%) and the placebo arm (75.0%).[6]

• Common TEAEs: The most frequently reported adverse events in patients receiving Lutikizumab were exacerbation of HS (10.6%), diarrhea (8.8%), headache (8.8%), pruritus (6.2%), and contact dermatitis (5.3%).[6]
• Serious Adverse Events (SAEs): SAEs were reported in 5.3% of patients in the combined Lutikizumab group, compared to 2.5% in the placebo group.[6]
• Events of Special Interest: Importantly, and in contrast to findings in the OA trials, there were no reported events of neutropenia and no Grade 3 or 4 laboratory evaluations of neutropenia observed in the HS study.[6] There were no deaths. One case of T-cell lymphoma was reported in a patient in the 300 mg EW arm who had pre-existing risk factors, including a history of HS and ongoing cigarette smoking.[6] This event will warrant careful monitoring in future long-term studies.

The Path Forward: Phase 3 Program "Intrepid" (NCT06468228)

Based on the strength of the Phase 2 data, AbbVie has advanced Lutikizumab into a comprehensive Phase 3 clinical program for HS, with the lead study titled "Intrepid".[6] This large-scale program, which is currently recruiting, is designed to confirm the efficacy and safety of Lutikizumab and support potential regulatory submissions.[35]

The study (NCT06468228) is a multicenter, randomized, double-blind, placebo-controlled trial planning to enroll approximately 1,280 adult and adolescent participants with moderate-to-severe HS.[35] Its sophisticated, multi-period design includes:

• Period 1 (16 weeks): A placebo-controlled induction period to confirm efficacy, where participants are randomized to receive either Lutikizumab or placebo every week.
• Period 2 (36 weeks): A maintenance period where participants who responded to Lutikizumab in Period 1 are re-randomized to different maintenance dosing regimens (every week vs. every other week) to determine optimal long-term treatment. Participants initially on placebo will cross over to receive active Lutikizumab treatment.
• Period 3 (Long-Term Extension): An open-label extension period where participants can continue to receive Lutikizumab for up to 140 weeks to gather long-term safety and efficacy data.
• US Sub-Study: An optional 156-week open-label sub-study for US participants to assess the long-term performance and usability of a prefilled pen delivery system.[35]

Broadening the Horizon: The Platform Study Program

In parallel with the pivotal Phase 3 program in hidradenitis suppurativa, AbbVie is employing a modern and efficient clinical trial strategy to explore the full potential of Lutikizumab across a range of other immune-mediated inflammatory diseases. The use of "platform studies"—master protocols designed to evaluate multiple therapies in one or more diseases simultaneously—allows for rapid and capital-efficient assessment of the drug's unique mechanism of action in different pathological contexts.[5] This approach treats Lutikizumab as a potential "portfolio-in-a-molecule," systematically testing its utility while also exploring potential synergies through combination therapies with other assets in AbbVie's immunology pipeline.

Rheumatoid Arthritis (RA) - NCT06972446

A Phase 2 platform study is currently recruiting adult participants with moderately to severely active RA who have had an inadequate response to one or two prior biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).[5] This trial includes multiple substudies to assess different therapeutic approaches:

• Substudy 1: Evaluates Lutikizumab as a monotherapy compared to placebo.
• Substudy 3: Evaluates Lutikizumab in combination with ravagalimab (another investigational agent) compared to placebo.[42]

Psoriatic Arthritis (PsA) - NCT06865105

Lutikizumab is also being investigated in a Phase 2, multicenter, randomized platform study for adults with active psoriatic arthritis who have failed one to two prior targeted therapies.[5] This open-label study is designed to assess both monotherapy and combination approaches, with participants randomized in a 1:1:1 ratio to one of three treatment arms:

• Lutikizumab monotherapy.
• Risankizumab monotherapy (an approved IL-23 inhibitor).
• A combination therapy of Lutikizumab and risankizumab.[43]

Ulcerative Colitis (UC) - NCT06257875

A Phase 2, multicenter, randomized study is evaluating Lutikizumab for induction and maintenance therapy in adult participants with moderately to severely active ulcerative colitis.[49] This trial, which is currently active but not recruiting, is designed to assess the safety and efficacy of Lutikizumab and includes an active comparator arm using adalimumab, a TNF inhibitor.[49] The study involves a 12-week induction period followed by a maintenance period up to week 52 for responders. While this study is ongoing, recent reports suggest that AbbVie may be discontinuing the development of Lutikizumab as a monotherapy for UC, though it may still be explored in combination therapy for Crohn's disease.[52]

Atopic Dermatitis (AD) - NCT06718101

The potential of Lutikizumab is being explored in a Phase 2 multicenter platform trial for adults with moderate-to-severe atopic dermatitis.[5] Sub-Study 1 of this trial is a randomized, placebo-controlled investigation of Lutikizumab monotherapy. Participants receive either Lutikizumab or placebo every other week for a 16-week induction period. This is followed by a treatment period where all participants receive open-label Lutikizumab for an additional 32 weeks, for a total study duration of 52 weeks.[44]

Integrated Analysis and Future Outlook

Lutikizumab stands as a testament to both the power of rational drug design and the critical importance of matching a novel mechanism to the correct disease pathophysiology. Its journey from a failed osteoarthritis candidate to a promising Phase 3 asset for hidradenitis suppurativa offers a compelling narrative on the nature of modern immunology drug development.

Competitive Landscape and Potential Positioning in HS

The treatment landscape for moderate-to-severe hidradenitis suppurativa has evolved significantly, but substantial unmet needs persist. According to treatment guidelines from bodies such as the American Academy of Dermatology (AAD) and the European Hidradenitis Suppurativa Foundation (EHSF), the therapeutic ladder typically begins with topical therapies and oral antibiotics (e.g., clindamycin and rifampicin).[55] For patients with more severe disease or who fail these initial treatments, biologic agents are recommended. The first class of biologics to show efficacy was TNF inhibitors, with adalimumab being a widely used standard of care.[55] More recently, IL-17 inhibitors like secukinumab have also been approved, providing another therapeutic option.[61]

Lutikizumab, with its novel dual IL−1α/β inhibitory mechanism, is poised to enter this landscape in a well-defined niche. The positive Phase 2 data were generated specifically in a population of patients who had already failed anti-TNF therapy.[6] This is a crucial differentiator. If the Phase 3 results are successful, Lutikizumab's most logical and valuable initial position in the market would be as a second- or third-line biologic agent for patients with moderate-to-severe HS who are refractory to or have lost response to TNF and/or IL-17 inhibitors. Its distinct mechanism of action provides a strong scientific rationale for its use in this population, where alternative pathways of inflammation are likely dominant.

Regulatory and Developmental Trajectory

Lutikizumab remains an investigational agent and has not been approved for any indication by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other global regulatory authority.[6] The FDA has assigned it a Unique Ingredient Identifier (UNII) code (15FAZ725S0) for tracking purposes.[16]

A significant regulatory milestone was achieved in May 2024, when AbbVie reached an agreement with the EMA's Paediatric Committee (PDCO) on a Paediatric Investigation Plan (PIP) for Lutikizumab in the treatment of hidradenitis suppurativa (EMEA-003481-PIP01-23).[65] A PIP outlines the plan for generating the necessary data to support the potential authorization of a medicine for use in children. An agreed-upon PIP is a mandatory prerequisite for submitting a Marketing Authorisation Application for adult indications in the European Union.[66] The agreement for Lutikizumab includes a deferral, meaning the pediatric studies can be conducted after the initial submission for adults. This agreement signals a clear and committed development path for Lutikizumab in Europe and is a critical step toward potential marketing authorization.

Concluding Remarks: A Tale of Precision Immunology

The development story of Lutikizumab offers a powerful case study in the modern era of precision immunology. It is a story of a sophisticated, rationally designed molecule whose clinical success has been entirely dependent on the underlying pathophysiology of the disease it is intended to treat. The starkly contrasting outcomes in osteoarthritis and hidradenitis suppurativa are highly instructive. In OA, despite clear evidence of target engagement, the clinical benefit was negligible, suggesting the IL-1 pathway is a subordinate or redundant player in the overall disease process for most patients. Conversely, in HS, where the IL-1 axis is strongly implicated as a central driver of inflammation, the same molecule produced robust and clinically meaningful efficacy.

The future of Lutikizumab now hinges on the outcomes of its pivotal Phase 3 program in HS. Success in these large-scale trials would not only provide a much-needed new therapeutic option for a suffering patient population but would also clinically validate the dual inhibition of IL−1α and IL−1β as a key therapeutic strategy in dermatology. The results from the ongoing platform studies in RA, PsA, UC, and AD will further define the ultimate therapeutic footprint of this unique molecule. Ultimately, the story of Lutikizumab is one of precision: a testament to the necessity of matching a highly specific therapeutic tool to the correct biological problem to unlock its full clinical potential.

Works cited

1. Lutikizumab - AbbVie - AdisInsight - Springer, accessed September 27, 2025, https://adisinsight.springer.com/drugs/800035747
2. CAS 1791411-57-8 Lutikizumab - BOC Sciences, accessed September 27, 2025, https://www.bocsci.com/product/lutikizumab-cas-1791411-57-8-461308.html
3. Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis - PMC - PubMed Central, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6390132/
4. lutikizumab | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 27, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=9297
5. Lutikizumab - Drug Targets, Indications, Patents - Patsnap Synapse, accessed September 27, 2025, https://synapse.patsnap.com/drug/8882dfd56df04489bd479980a6e9c68b
6. Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3 - AbbVie News Center, accessed September 27, 2025, https://news.abbvie.com/2024-01-08-Lutikizumab-Showed-Positive-Results-in-a-Phase-2-Trial-of-Adults-with-Moderate-to-Severe-Hidradenitis-Suppurativa-as-Program-Advances-to-Phase-3
7. Is Lutikizumab, an Anti–Interleukin-1α/β Dual Variable Domain Immunoglobulin, efficacious for Osteoarthritis? Results from a bayesian network meta-analysis - PubMed Central, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7661137/
8. (PDF) Is Lutikizumab, an Anti–Interleukin-1α/β Dual Variable Domain Immunoglobulin, efficacious for Osteoarthritis? Results from a bayesian network meta-analysis - ResearchGate, accessed September 27, 2025, https://www.researchgate.net/publication/346723460_Is_Lutikizumab_an_Anti-Interleukin-1ab_Dual_Variable_Domain_Immunoglobulin_efficacious_for_Osteoarthritis_Results_from_a_bayesian_network_meta-analysis
9. Biologic Lutikizumab Didn't Seem to Improve Knee Osteoarthritis in a Recent Trial, accessed September 27, 2025, https://creakyjoints.org/about-arthritis/osteoarthritis/oa-treatment/lutikizumab-not-effective-knee-osteoarthritis/
10. Lutikizumab Demonstrates Positive Results in Phase 2 Trial for ..., accessed September 27, 2025, https://www.dermatologytimes.com/view/lutikizumab-demonstrates-positive-results-in-phase-2-trial-for-hidradenitis-suppurativa
11. Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3 - PR Newswire, accessed September 27, 2025, https://www.prnewswire.com/news-releases/lutikizumab-showed-positive-results-in-a-phase-2-trial-of-adults-with-moderate-to-severe-hidradenitis-suppurativa-as-program-advances-to-phase-3-302027605.html
12. AbbVie's Lutikizumab Shows Promise in Treating Moderate to Severe Hidradenitis Suppurativa - Pharmaceutical Executive, accessed September 27, 2025, https://www.pharmexec.com/view/abbvie-s-lutikizumab-shows-promise-in-treating-moderate-to-severe-hidradenitis-suppurativa
13. Lutikizumab: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed September 27, 2025, https://go.drugbank.com/drugs/DB16224
14. Lutikizumab - KEGG DRUG, accessed September 27, 2025, https://www.kegg.jp/entry/D12370
15. Lutikizumab - PharmaKB, accessed September 27, 2025, https://www.pharmakb.com/drug-report/lutikizumab
16. UNII - 15FAZ725S0, accessed September 27, 2025, https://precision.fda.gov/uniisearch/srs/unii/15FAZ725S0
17. Anti-IL-1a & IL1b Antibody (Lutikizumab), accessed September 27, 2025, https://www.apexbt.com/downloader/document/F1394/Datasheet.pdf
18. Lutikizumab (ABT-981) | Anti-IL-1α/β Immunoglobulin | MedChemExpress, accessed September 27, 2025, https://www.medchemexpress.com/lutikizumab.html
19. Lutikizumab | MedPath, accessed September 27, 2025, https://trial.medpath.com/drug/50613906ca374923/lutikizumab
20. Lutikizumab Active Not Recruiting Phase 2 Trials for Hidradenitis Suppurativa (HS) Treatment | DrugBank Online, accessed September 27, 2025, https://go.drugbank.com/drugs/DB16224/clinical_trials?conditions=DBCOND0054533&phase=2&purpose=treatment&status=active_not_recruiting
21. Definition of lutikizumab - NCI Drug Dictionary, accessed September 27, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lutikizumab
22. Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable d - Annals of the Rheumatic Diseases, accessed September 27, 2025, https://ard.bmj.com/content/annrheumdis/78/3/413.full.pdf
23. Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis | Annals of the Rheumatic Diseases, accessed September 27, 2025, https://ard.bmj.com/content/78/3/413
24. Lutikizumab | CAS NO.:1791411-57-8 | GlpBio, accessed September 27, 2025, https://www.glpbio.com/lutikizumab.html
25. ard.bmj.com, accessed September 27, 2025, https://ard.bmj.com/content/78/3/413#:~:text=Lutikizumab%20(ABT%2D981)%2C,family%20members%20including%20IL%2D1Ra.
26. A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis - PubMed, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/30653843/
27. A Phase 2 Trial of Lutikizumab, an Anti-interleukin 1Alpha/Beta Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients with Synovitis | Quanterix, accessed September 27, 2025, https://www.quanterix.com/posters/phase-2-trial-lutikizumab-anti-interleukin-1alphabeta-dual-variable/
28. A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis - University of Copenhagen Research Portal, accessed September 27, 2025, https://researchprofiles.ku.dk/en/publications/a-phase-ii-trial-of-lutikizumab-an-anti-interleukin-1%CE%B1%CE%B2-dual-vari
29. SAT0576 Biomarkers predictive of pain improvement in knee osteoarthritis subjects treated with the anti-il-1 alpha/beta dual variable domain immunoglobulin lutikizumab (ABT-981) | Annals of the Rheumatic Diseases, accessed September 27, 2025, https://ard.bmj.com/content/77/Suppl_2/1142.1
30. Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis - PubMed, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/30552176/
31. Lutikizumab (ABT-981) | CAS 1791411-57-8 | AbMole BioScience, accessed September 27, 2025, https://www.abmole.com/products/lutikizumab.html
32. Is Lutikizumab, an Anti-Interleukin-1 α/ β Dual Variable Domain Immunoglobulin, efficacious for Osteoarthritis? Results from a bayesian network meta-analysis - PubMed, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/33204726/
33. A Phase II Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis - Semantic Scholar, accessed September 27, 2025, https://www.semanticscholar.org/paper/A-Phase-II-Trial-of-Lutikizumab%2C-an-%CE%B2-Dual-Variable-Fleischmann-Bliddal/dbe968fc92ba6b3d3ab297787ec680ea08d076b8
34. A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy - Abbvie Clinical Trials, accessed September 27, 2025, https://www.abbvieclinicaltrials.com/study/?id=M20-262
35. Study Details | NCT06468228 | A Study to Assess Disease Activity ..., accessed September 27, 2025, https://clinicaltrials.gov/study/NCT06468228
36. Phase 2 Success: Lutikizumab Advances to Phase 3 in Treating Moderate to Severe HS, accessed September 27, 2025, https://synapse.patsnap.com/article/phase-2-success-lutikizumab-advances-to-phase-3-in-treating-moderate-to-severe-hs
37. HS Pipeline Watch: Abbvie's Lutikizumab Advances to Phase 3 in HS - The Dermatology Digest, accessed September 27, 2025, https://thedermdigest.com/hs-pipeline-watch-abbvies-lutikizumab-advances-to-phase-3-in-hs/
38. HS: Targeting IL-1 pathway potential option after anti-TNF failure - Medical Conferences, accessed September 27, 2025, https://conferences.medicom-publishers.com/specialisation/dermatology/aad-2024/hs-targeting-il-1-pathway-potential-option-after-anti-tnf-failure/
39. Late-Breaking Data: Lutikizumab Shows Positive Results in Difficult-to-Treat HS After Failed TNF Therapy | Dermatology Times, accessed September 27, 2025, https://www.dermatologytimes.com/view/late-breaking-data-lutikizumab-shows-positive-results-in-difficult-to-treat-hs-after-failed-tnf-therapy
40. Discussing New Phase 2 Findings on Lutikizumab for Hidradenitis Suppurativa with Alexa Kimball, MD, MPH | HCPLive, accessed September 27, 2025, https://www.hcplive.com/view/discussing-new-phase-2-findings-on-lutikizumab-for-hidradenitis-suppurativa-with-alexa-kimball-md-mph
41. Lutikizumab Recruiting Phase 3 Trials for Hidradenitis Suppurativa (HS) Treatment, accessed September 27, 2025, https://go.drugbank.com/drugs/DB16224/clinical_trials?conditions=DBCOND0054533&phase=3&purpose=treatment&status=recruiting
42. NCT06972446 | A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | ClinicalTrials.gov, accessed September 27, 2025, https://www.clinicaltrials.gov/study/NCT06972446
43. Study Details | NCT06865105 | Study of Targeted Therapies for the ..., accessed September 27, 2025, https://clinicaltrials.gov/study/NCT06865105
44. Study Details | NCT06718101 | A Study to Evaluate the ..., accessed September 27, 2025, https://clinicaltrials.gov/study/NCT06718101
45. Study Details | NCT06972446 | A Study to Evaluate Different ..., accessed September 27, 2025, https://clinicaltrials.gov/study/NCT06972446
46. Rheumatoid Arthritis - NCT06972446 - AbbVie - MedSearch Global, accessed September 27, 2025, https://medsearchglobal.com/antistudydetail/NCT06972446
47. A Study to Evaluate Different Targeted Therapies for - ClinConnect, accessed September 27, 2025, https://clinconnect.io/trials/NCT06972446
48. A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis, accessed September 27, 2025, https://trials.arthritis.org/trials/NCT06972446
49. NCT06257875 | A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis | ClinicalTrials.gov, accessed September 27, 2025, https://www.clinicaltrials.gov/study/NCT06257875
50. A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis - Mayo Clinic, accessed September 27, 2025, https://www.mayo.edu/research/clinical-trials/cls-20574787
51. A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis - Clinical Trials, accessed September 27, 2025, https://www.allclinicaltrials.com/study/NCT06257875
52. AbbVie's IL-1 asset misses mark as monotherapy in phase 2 ulcerative colitis study, accessed September 27, 2025, https://www.fiercebiotech.com/biotech/abbvies-il-1-asset-misses-mark-monotherapy-phase-2-ulcerative-colitis-study
53. Lutikizumab Recruiting Phase 2 Trials for Atopic Dermatitis / Hidradenitis Suppurativa (HS) Basic Science | DrugBank Online, accessed September 27, 2025, https://go.drugbank.com/drugs/DB16224/clinical_trials?conditions=DBCOND0028414%2CDBCOND0054533&phase=2&purpose=basic_science&status=recruiting
54. A Phase 2 Multicenter Platform Trial of Targeted Immunomodulator Therapies for Moderate to Severe Atopic Dermatitis | MedPage Today, accessed September 27, 2025, https://www.medpagetoday.com/clinical-trial-finder/study/NCT06718101?category=dermatology&topic=atopic-dermatitis
55. Hidradenitis suppurativa - Diagnosis and treatment - Mayo Clinic, accessed September 27, 2025, https://www.mayoclinic.org/diseases-conditions/hidradenitis-suppurativa/diagnosis-treatment/drc-20352311
56. Hidradenitis suppurativa: Diagnosis and treatment - American Academy of Dermatology, accessed September 27, 2025, https://www.aad.org/public/diseases/a-z/hidradenitis-suppurativa-treatment
57. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management - PMC, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9131892/
58. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa - PMC, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5156664/
59. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa, accessed September 27, 2025, https://ehsf.eu/wp-content/uploads/2019/10/European-Guidelines.pdf
60. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa - PubMed, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/25640693/
61. University of Groningen European S2k guidelines for hidradenitis suppurativa/acne inversa part 2, accessed September 27, 2025, https://research.rug.nl/files/1189519630/Acad_Dermatol_Venereol_-_2024_-_Zouboulis_-_European_S2k_guidelines_for_hidradenitis_suppurativa_acne_inversa_part_2_.pdf
62. Practical Guidelines for Managing Patients With Hidradenitis Suppurativa: An Update, accessed September 27, 2025, https://hsfoundation.ca/wp-content/uploads/2022/10/JCMS-Hidradenitis-Suppurativa-Practical-Guidelines-CHSF-Paper-August-2022-2.pdf
63. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - ERN Skin, accessed September 27, 2025, https://ern-skin.eu/wp-content/uploads/2020/08/Recommendations-HS-ALLIANCE.pdf
64. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/39699926/
65. EMEA-003481-PIP01-23 - paediatric investigation plan | European ..., accessed September 27, 2025, https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003481-pip01-23
66. Paediatric investigation plans | European Medicines Agency (EMA), accessed September 27, 2025, https://www.ema.europa.eu/en/human-regulatory-overview/research-development/paediatric-medicines-research-development/paediatric-investigation-plans
67. EMA Guidance on Paediatric Investigation Plans - Pharmaceutical Technology, accessed September 27, 2025, https://www.pharmtech.com/view/ema-guidance-on-paediatric-investigation-plans
68. CINCLUS PHARMA AGREES ON PEDIATRIC INVESTIGATION PLAN (PIP) WITH EMA - MFN.se, accessed September 27, 2025, https://storage.mfn.se/9ee98d3e-cf13-4a9e-8b23-a26c63fd982f/cinclus-pharma-agrees-on-pediatric-investigation-plan-pip-with-ema.pdf